drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Oral tyrosine kinase inhibitor active against NTRK1/2/3, ROS1, and ALK fusion kinases.
nci_thesaurus_concept_id
C114984
nci_thesaurus_definition
An orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1 and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express these kinases. TrkA, TrkB, TrkC, ROS1 and ALK are overexpressed in a variety of cancer cell types.
drug_mesh_term
entrectinib
drug_category
SMALL MOLECULE DRUG
drug_class
Inhibitor
drug_delivery_route
Oral
drug_mechanism_of_action
Oral tyrosine kinase inhibitor that selectively targets TRKA/B/C (NTRK1/2/3), ROS1, and ALK fusion kinases, blocking their signaling (e.g., MAPK and PI3K pathways) to inhibit tumor proliferation and induce apoptosis in fusion-positive cancers.
drug_name
Entrectinib
nct_id_drug_ref
NCT05862285